CD28 Superagonistic Activation of T Cells Induces a Tumor Cell-Like Metabolic Program
| Author | Thaventhiran T. |
| Author | Wong W. |
| Author | Alghanem A.F. |
| Author | Alhumeed N. |
| Author | Aljasir M.A. |
| Author | Ramsey S. |
| Author | Sethu S. |
| Author | Yeang H.X.A. |
| Author | Chadwick A.E. |
| Author | Cross M. |
| Author | Webb S.D. |
| Author | Djouhri L. |
| Author | Ball C. |
| Author | Stebbings R. |
| Author | Sathish J.G. |
| Available date | 2020-04-16T06:56:46Z |
| Publication Date | 2019 |
| Publication Name | Monoclonal Antibodies in Immunodiagnosis and Immunotherapy |
| Resource | Scopus |
| ISSN | 21679436 |
| Abstract | CD28 superagonist (CD28SA), a therapeutic immunomodulatory monoclonal antibody triggered rapid and exaggerated activation of CD4+ effector memory T cells (TEMs) in humans with unwanted serious adverse effects. It is well known that distinct metabolic programs determine the fate and responses of immune cells. In this study, we show that human CD4+ TEMs stimulated with CD28SA adopt a metabolic program similar to those of tumor cells with enhanced glucose utilization, lipid biosynthesis, and proliferation in hypoxic conditions. Identification of metabolic profiles underlying hyperactive T cell activation would provide a platform to test safety of immunostimulatory antibodies. |
| Sponsor | This work was supported by funding from the Medical Research Council, United Kingdom (G1000397-2/1). |
| Language | en |
| Publisher | Mary Ann Liebert Inc. |
| Subject | CD28 superagonist CD4+ effector memory T cells glycolysis lipogenesis oxidative phosphorylation |
| Type | Article |
| Pagination | 60-69 |
| Issue Number | 2 |
| Volume Number | 38 |
Files in this item
This item appears in the following Collection(s)
-
Center for Advanced Materials Research [1327 items ]